Under the expanded deal, PredictImmune will have first right of refusal on technologies for predicting disease outcome for systemic lupus erythematosus.
The firm said CRISPR will enable targeted sequencing of long regions of interest that were previously only accessible with long-read whole-genome sequencing.
The technology uses a proprietary chemistry that attaches primers to probes with a polyethylene glycol-based linker to prevent the formation of primer-dimers.
The Broad will now offer licenses for both its own CRISPR IP and MilliporeSigma's to companies using CRISPR in their research and development activities.
Mirnax will use Arcis' nucleic acid sample preparation and preservation technology to improve the stability of miRNA biomarkers for early disease detection.
Oncore and its partners will commercialize GeneNews' ColonSentry test in all countries outside the US and Canada under the five-year exclusive agreement
ERS Genomics was founded to provide access to foundational CRISPR-Cas9 IP held by Emmanuelle Charpentier for applications other than human disease treatment.
Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.
